# A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants

> **NCT07671391** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Obesity Adult Onset

## Interventions

- **DRUG:** LAE102 +Tirzepatide
- **DRUG:** LAE102 placebo,+Tirzepatide

## Key facts

- **NCT ID:** NCT07671391
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-07
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671391, "A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*